---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/266203378.md"
description: "Novo Nordisk: The pricing of weight loss drugs for self-paying patients is lower than Eli Lilly"
datetime: "2025-11-17T12:44:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266203378.md)
  - [en](https://longbridge.com/en/news/266203378.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266203378.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/266203378.md) | [繁體中文](https://longbridge.com/zh-HK/news/266203378.md)


# 

Novo Nordisk: The pricing of weight loss drugs for self-paying patients is lower than Eli Lilly

### Related Stocks

- [Novo Nordisk A/S (NVO.US)](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [<![CDATA[Novo Nordisk Launches Multi-Month Subscription Program for Wegovy ]]>](https://longbridge.com/en/news/281216333.md)
- [Novo Nordisk slashes Wegovy prices to court uninsured patients](https://longbridge.com/en/news/281206892.md)
- [Eli Lilly: Foundayo will be available via LillyDirect starting at $25/month with commercial coverage and $149 for self-pay](https://longbridge.com/en/news/281395539.md)
- [ELI LILLY: FOUNDAYO WILL BE AVAILABLE VIA LILLYDIRECT STARTING AT $25/MONTH WITH COMMERCIAL COVERAGE & $149 FOR SELF-PAY](https://longbridge.com/en/news/281397115.md)
- [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/en/news/281323250.md)